Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants [0.03%]
一种针对SARS-CoV-2变异毒株的超高亲和力及中和能力的嵌合ACE-2/Fc型融合蛋白的设计
Neil M Bodie,Rina Hashimoto,David Connolly et al.
Neil M Bodie et al.
Background: As SARS-CoV-2 continues to mutate into Variants of Concern (VOC), there is growing and urgent need to develop effective antivirals to combat COVID-19. Monoclonal antibodies developed earlier are no longer capa...
Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics [0.03%]
早期发现阶段的可开发性评估以促进抗体类药物的研发
Weijie Zhang,Hao Wang,Nan Feng et al.
Weijie Zhang et al.
Developability refers to the likelihood that an antibody candidate will become a manufacturable, safe and efficacious drug. Although the safety and efficacy of a drug candidate will be well considered by sponsors and regulatory agencies, de...
Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15R α complex [0.03%]
IAP0971的临床前评估，这是一种新型免疫细胞因子，可特异性结合PD1并融合IL15/IL15Rα复合物
Jihong Chen,Ziyou Shen,Xiaoling Jiang et al.
Jihong Chen et al.
Background: Currently, cytokine therapy for cancer has demonstrated efficacy in certain diseases but is generally accompanied by severe toxicity. The field of antibody-cytokine fusion proteins (immunocytokines) arose to t...
Comparative Assessment of the Binding and Neutralisation Activity of Bispecific Antibodies Against SARS-CoV-2 Variants [0.03%]
针对SARS-CoV-2变异株的双特异性抗体的结合和中和活性的比较评估
Alexis Q Dean,Charles B Stauft,Julianne D Twomey et al.
Alexis Q Dean et al.
Background: Neutralising antibodies against SARS-CoV-2 are a vital component in the fight against COVID-19 pandemic, having the potential of both therapeutic and prophylactic applications. Bispecific antibodies (BsAbs) ag...
Ceramic hydroxyapatite chromatography plays a critical role in bispecific antibody purification process for impurity removal [0.03%]
陶瓷羟基磷灰石层析在双特异性抗体纯化过程中去杂质起着关键作用
Jessica A Waller,Ji Zheng,Rachel Dyer et al.
Jessica A Waller et al.
Background: Significant challenges exist in downstream purification of bispecific antibodies (BsAbs) due to the complexity of BsAb architecture. A unique panel of mispaired species can result in a higher level of product-...
A novel humanized Chi3l1 blocking antibody attenuates acetaminophen-induced liver injury in mice [0.03%]
新型人源化Chi3l1阻断抗体减轻小鼠由对乙酰氨基酚引起的肝损伤
Leike Li,Yankai Wen,Daniel Wrapp et al.
Leike Li et al.
Acetaminophen (APAP) overdose is a leading cause of acute liver injury in the USA. The chitinase 3-like-1 (Chi3l1) protein contributes to APAP-induced liver injury (AILI) by promoting hepatic platelet recruitment. Here, we report the develo...
Engineering antibody and protein therapeutics to cross the blood-brain barrier [0.03%]
工程改造抗体和蛋白质药物以穿越血脑屏障
Peng Zhao,Ningyan Zhang,Zhiqiang An
Peng Zhao
Diseases in the central nervous system (CNS) are often difficult to treat. Antibody- and protein-based therapeutics hold huge promises in CNS disease treatment. However, proteins are restricted from entering the CNS by the blood-brain barri...
Vector design for enhancing expression level and assembly of knob-into-hole based FabscFv-Fc bispecific antibodies in CHO cells [0.03%]
优化表达水平和基于柄-孔FabscFv-Fc双特异性抗体组装的向量设计在CHO细胞中的应用
Han Kee Ong,Ngan T B Nguyen,Jiawu Bi et al.
Han Kee Ong et al.
Background: Two-armed FabscFv-Fc is a favoured bispecific antibody (BsAb) format due to its advantages of the conventional IgG structure. Production of FabscFv-Fc requires expression of three polypeptide chains, one light...
Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa [0.03%]
抗体工程在从MOv19单克隆抗体生成衍生物中的作用：针对叶酸受体阿尔法的40年生物/治疗工具
Barbara Frigerio,Matilde Montermini,Canevari Silvana et al.
Barbara Frigerio et al.
In the 1980s, we developed and characterized numerous murine monoclonal antibodies (MAbs) directed against human tumor-associated antigens. This mini review is focused on the generation of derivatives of an anti-folate receptor α (FRα) MA...
The emergence of AntibodyPlus: the future trend of antibody-based therapeutics [0.03%]
抗体药物的发展趋势：从单克隆抗体到双特异性抗体及其后的时代
Yong Zhu,Shawn Shouye Wang,Zhaohui Sunny Zhou et al.
Yong Zhu et al.
To date, close to 100 canonical monoclonal antibody drugs have been approved by the FDA; furthermore, a number of antibody-derived therapeutics in nontraditional formats have reached late development stages and the market, and many more are...